[吉非替尼（易瑞沙）对肺腺癌的肿瘤反应：迈向治疗靶点的分子基础] - Suppr | 超能文献

[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].

作者信息

Madelaine J, Cadranel J, Zalcman G

出版信息

Rev Mal Respir. 2004 Nov;21(5 Pt 1):881-5. doi: 10.1016/s0761-8425(04)71466-7.

DOI:10.1016/s0761-8425(04)71466-7

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].[吉非替尼（易瑞沙）对肺腺癌的肿瘤反应：迈向治疗靶点的分子基础]

Rev Mal Respir. 2004 Nov;21(5 Pt 1):881-5. doi: 10.1016/s0761-8425(04)71466-7.

2

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.表皮生长因子受体中的激活突变是非小细胞肺癌对吉非替尼产生反应的基础。

N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.

3

Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.表皮生长因子受体酪氨酸激酶的突变可能预测非小细胞肺癌对吉非替尼的反应。

Clin Lung Cancer. 2004 May;5(6):331-2. doi: 10.1016/s1525-7304(11)70182-6.

4

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.肺癌中的表皮生长因子受体（EGFR）突变：与吉非替尼治疗临床反应的相关性

Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.

5

Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.吉非替尼在非小细胞肺癌中的临床开发及肺癌易瑞沙生存评估试验

Clin Lung Cancer. 2005 Jan;6(4):214-6. doi: 10.1016/s1525-7304(11)70473-9.

6

Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.肿瘤微环境中 podoplanin 阳性的癌相关成纤维细胞诱导 EGFR 突变肺腺癌对 EGFR-TKIs 的原发性耐药。

Clin Cancer Res. 2015 Feb 1;21(3):642-51. doi: 10.1158/1078-0432.CCR-14-0846. Epub 2014 Nov 11.

7

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.肺腺癌初始携带有敏感 EGFR 突变，一线吉非替尼和二线细胞毒化疗获得性耐药。

BMC Pharmacol Toxicol. 2017 May 10;18(1):21. doi: 10.1186/s40360-017-0130-0.

8

EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.表皮生长因子受体（EGFR）突变L747P导致一名中国肺腺癌患者对吉非替尼产生耐药，并加速了肝转移。

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8603-6. eCollection 2015.

9

Targeting targeted therapy.靶向靶向治疗。

N Engl J Med. 2004 May 20;350(21):2191-3. doi: 10.1056/NEJMe048101. Epub 2004 Apr 29.

10

Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.白细胞端粒长度与表皮生长因子受体酪氨酸激酶抑制剂治疗晚期肺腺癌患者的临床结局。

DNA Cell Biol. 2018 Nov;37(11):903-908. doi: 10.1089/dna.2018.4337. Epub 2018 Oct 2.